Internal restructuring
île de France;
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.1 - Manufacture of basic pharmaceutical products

180 - 220 jobs
Number of planned job losses
Job loss
Announcement Date
18 July 2014
Employment effect (start)
1 September 2014
Foreseen end date


US pharmaceutical group Bristol-Myers Squibb (BMS) has decided to close its European headquarters located in Rueil-Malmaison (France). As reported, 220 jobs are to be affected including 120 employees with employment contracts under the French labour law. As announced, the activities of the French site will be relocated to other BMS sites in Europe, possibly in France, London and/or Brussels. In addition, the sources refer to 60 job cuts that will affect the French BMS subsidiary as a part of a global restructuring plan.

In total180 employees with French labour law contracts will lose their job. As mentioned, the group has already launched several social plans in France during the last 8 years. According to the sources, with a significant loss of patents and parts of its business such medical imaging products, the job reduction measure is aiming at boosting the firm’s competitiveness. BMS has initiated a global restructuring plan announced in 2007.


  • 23 July 2014: Le Parisien
  • 18 July 2014: Les Echos


Eurofound (2014), BMS, Internal restructuring in France, factsheet number 77340, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/77340.